Establishment of an enzyme-linked immunosorbent assay (ELISA) for measuring cellular MAGE-4 protein on human cancers

Shichijo, Shigeki; Tsunosue, Rika; Kubo, Keisuke; Kuramoto, Terukazu; Tanaka, Yasuyuki; Hayashi, Akihiko; Itoh, Kyogo

doi:10.1016/0022-1759(95)00145-z

Cited by 16 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found to correspond to MAGE‐4, a protein expressed in various human cancers 14. The reported apparent molecular weight of MAGE‐4 of 45 kDa 15 is close to that observed for the 2B4 target protein in H1299. The 2B4 antibody recognizes the epitope GEGPSTGPR, corresponding to amino acids (aa) 443–451 of EBNA1 (data not shown).…”

Section: Resultssupporting

confidence: 66%

Degree of crosslinked cotton cellulose with prereacted DMDHEU–AA

Chen

Yao

Chen

et al. 2001

J of Applied Polymer Sci

View full text Add to dashboard Cite

Dimethyloldihydroxyethyleneurea (DMDHEU) and acrylic acid (AA) were used to synthesize the dimethyloldihydroxyethyleneurea-acrylic acid product (DMD-HEU-AA, mole ratios of DMDHEU/AA ϭ 1/0, 1/1, and 1/2, respectively). Cotton fabrics were treated with the various prereacted DMDHEU-AA products by changing resin concentrations in the bath. We found that the dry crease recovery angle (DCRA) and wet crease recovery angle (WCRA) of the treated fabrics increased with the increase of acrylic acid in the prereacted DMDHEU-AA at the same value of resin concentration in the bath, whereas the tensile strength retention (TSR) showed the inverse tendency. For a given value of number of crosslinks per anhydroglucose unit (CL/AGU), the DCRA and WCRA values of the DMDHEU-AA-treated fabrics were higher than those for DMDHEU-treated fabrics. Additionally, agent distribution and the reaction between -COOH of the crosslinking agent and cellulose molecule were also investigated in this study.

show abstract

Section: Resultssupporting

confidence: 66%

Degree of crosslinked cotton cellulose with prereacted DMDHEU–AA

Chen

Yao

Chen

et al. 2001

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…This ELISA indicated no apparent cross-reactivity with the products of the other closely related MAGE genes (Shichijo et al, 1995a,b). We have shown that MAGE-4 (4a and 4b) mRNA was expressed in more than one-fourth of HN-SCC (Eura et al, 1995), and that MAGE-4 protein was detectable in cancer tissues from 7 of 10 lung SCC (Shichijo et al, 1995b). This study showed that the serum level of MAGE-4 protein in HN-SCC patients was significantly higher than that of the NMD, VOL or HD groups, and that serum MAGE-4 protein was positive (.1.15 ng/ml) in sera of 28 (29%) of 96 HN-SCC patients.…”

Section: Resultsmentioning

confidence: 99%

“…Detection of the MAGE-4 protein in human sera or culture supernatants of cell lines was carried out by sandwich ELISA using a mouse monoclonal antibody (MAb), (IgG 1 , R5 MAb) and a biotinylated polyclonal rabbit affinity-purified IgG antibody against MAGE-4 protein, as reported by Shichijo et al (1995b). Briefly, 10 µg/ml R5 MAb solution (100 µl per well) was dispensed into wells of 96-well plates and incubated overnight at 4°C.…”

Section: Detection Of Mage-4 Protein By Elisamentioning

confidence: 99%

Detection of MAGE-4 protein in sera of patients with head-and-neck squamous-cell carcinoma

et al. 1997

Self Cite

View full text Add to dashboard Cite

The MAGE-4 gene, a member of the MAGE gene family, is expressed in various cancers, including head-and-neck squamous-cell carcinomas (HN-SCC), but is not expressed in any normal tissues except for the testis and placenta. The aim of this study was to determine whether serum MAGE-4 protein is a useful tumor marker for detection of HN-SCC. An enzyme-linked immunosorbent assay was used to measure serum level of MAGE-4 protein. The serum level of MAGE-4 in pre-operative HN-SCC patients was significantly higher than that in patients with non-malignant diseases (NMD) of the head and neck, volunteers undergoing cancer screening (VOL), or healthy donors (HD). When the cut-off level was determined at 1.15 ng/ml (mean plus 3 SD of HD), sera from 28 of 96 patients with HN-SCC (p F 0.0001 vs. the other groups), 7 of 82 patients with NMD, 2 of 92 with VOL, and 0 of 68 HD were positive for MAGE-4. Serum levels of MAGE-4 protein in all 7 HN-SCC patients whose sera were positive for MAGE-4 before operation decreased after operation, and, in one patient, a renewed rise in serum level was followed by recurrence. These results indicate that MAGE-4 protein is detectable in sera of a significant number of HN-SCC patients, and that serum MAGE-4 protein might be a useful tumor marker to monitor the recurrence of MAGE-4-positive HN-SCC. Int. J. Cancer, 70:287-290, 1997.r 1997 Wiley-Liss, Inc.The MAGE gene family consists of at least 12 closely related genes located on the long arm of chromosome X ( Van der Bruggen et al., 1991;Traversari et al., 1992;Gaugler et al., 1994;De Plaen et al., 1994). Among them, the MAGE-1 or -3 gene codes for tumor antigens on HLA-A1 and -Cw1601 or -A1 and -A2 recognized by cytotoxic T lymphocytes Van der Bruggen et al., 1994a,b). genes are preferentially expressed at the mRNA level in many different cancers, including head-and-neck squamous-cell carcinoma (HN-SCC) (Van der Bruggen et al., 1991; 1994a,b;Traversari et al., 1992;Gaugler et al., 1994;De Plaen et al., 1994;Weynants et al., 1994; Shichijo et al., 1995a,b;Eura et al., 1995). In contrast, no normal cells other than testis and placenta express the MAGE genes (Weynants et al., 1994;Takahashi et al., 1995). We have developed an enzymelinked immunosorbent assay (ELISA) for detection of MAGE-4 protein (Shichijo et al., 1995a,b). The present study addresses the question of whether serum MAGE-4 protein is a useful tumor marker for detection of HN-SCC. MATERIAL AND METHODS Sample collectionPeripheral blood was obtained from 96 pre-operative HN-SCC patients, and 82 patients with non-malignant diseases (NMD) of the head and neck (dental caries, periodontal disease, fracture, cyst, benign tumor, odontogenic infection, sinusitis, tonsillitis and pharyngitis) on their initial visit to the out-patients' clinic of the Department of Oral Surgery of the Kurume University School of Medicine, or the Department of Otolaryngology of Kumamoto University School of Medicine. The control sera were obtained from 68 healthy donors (HD). The mean age of the HD was much l...

show abstract

“…MAGE-A genes are therefore regarded as attractive candidates for specific immunotherapy and clinical trials of cancer patients involving immunization with MAGE-A1 and 3 peptides are in progress (Marchand et al, 1999;Nestle et al, 1998). Monoclonal antibodies (MAbs) against MAGE-1, 3, 4 and 11 proteins have been developed using the respective recombinant E. coli proteins as immunogen (Chen et al, 1994;Kocher et al, 1995;Shichijo et al, 1995;Carrel et al, 1996;Jurk et al, 1998) MAGE-10 (Carrel et al, 1996;Rimoldi et al, 1999).To MAGE-3, Kocher et al, 1995) in melanoma Me242 and Me244 cells (expressing only MAGE-2/6 and 1/2/6/10, respectively) and fibrosarcoma Table I …”

mentioning

confidence: 99%